Supplemental Table 1 from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins

Tumors were implanted and INDUKINE treatment was performed as described in Figure 2. RNA from each tumor was isolated on day 5 and subjected to immune profiling with the NanoString nCounter PanCancer Mouse Immune Profiling panel. Table includes the Z scores of transcripts with statistically significant differences (p < 0.05) in expression between the vehicle group and either treatment group. Each column represents the gene expression profile of the tumor from an individual animal.